Jiangsu Hengrui Medicine (SHA:600276) obtained approval from China's drug administrator to begin clinical trials for its ruiveris tablets, according to a filing with the Shanghai bourse.
The trials will investigate the second-generation androgen receptor inhibitor ruiveris in combination with HS-20093 for injection to treat prostate cancer.
Shares of the pharmaceutical company slid 1% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.